文献速递乳房整形与再造创面修复

术后预防性抗生素能否减少高毒力感染?660例组织扩张器乳房再造分析

Do Postoperative Prophylactic Antibiotics Reduce Highly Virulent Infections?: An Analysis of 660 Tissue Expander Breast Reconstructions.
PubMed 文献 · Ann Plast Surg · 2020-01-01

单机构2001-2018年660例即刻组织扩张器乳房再造回顾性研究,比较两种预防性抗生素方案对手术部位感染细菌谱和假体丢失的影响。结果显示延长术后抗生素未减少高毒力感染或假体丢失,但组2革兰阳性菌和金黄色葡萄球菌发生率显著更高。

要点

  • 延长术后抗生素未降低高毒力感染或假体丢失率
  • 短程静脉抗生素组革兰阳性菌和金黄色葡萄球菌感染率更高
  • 应推进抗生素管理指南,避免过度使用延长预防方案

核心结论

  • 延长术后抗生素使用未预防高毒力感染或假体丢失。
  • 应考虑制定反对过度使用延长预防方案的抗生素管理指南。

研究设计与样本

  • 单机构2001-2018年即刻组织扩张器乳房再造的回顾性研究,共660例TEBR。
  • 纳入二期手术前需住院的手术部位感染,比较两种预防性抗生素方案。

主要发现

  • 660例TEBR中85例(12.9%)发生需住院的SSI。
  • 组1培养阳性SSI为64%(n=36),组2为83%(n=24),P=0.076。
  • 组2革兰阳性菌发生率显著更高(46.4% vs 72.4%,P=0.022),金黄色葡萄球菌亦显著更高(21.4% vs 55.2%,P=0.002)。
  • 两组高毒力菌(P=0.168)、革兰阴性菌(P=0.416)、总分离菌(P=0.192)及假体丢失(62.5% vs 62.1%,P=0.969)均无显著差异。

关键数值与推荐

  • 高毒力菌定义为ESKAPE病原体:屎肠球菌、金黄色葡萄球菌、肺炎克雷伯菌、鲍曼不动杆菌、铜绿假单胞菌、肠杆菌属。
  • 假体丢失定义为移除组织扩张器且未即刻替换。
  • 组1:<24小时围手术期静脉抗生素+出院后口服抗生素;组2:仅<24小时静脉抗生素。

临床怎么用

  • 组织扩张器乳房再造术后不必常规延长预防性抗生素以预防高毒力感染或假体丢失。
  • 应遵循抗生素管理原则,避免过度使用延长预防方案。

局限性

  • 单机构回顾性研究。
  • 需进一步分析SSI发生时间和抗生素治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many surgeons are reluctant to discontinue prophylactic antibiotics after 24 hours in tissue expander breast reconstruction (TEBR) because of fear of increased risk of surgical site infection (SSI). Currently, there is no consensus regarding antibiotic prophylaxis duration in TEBR. In addition, there remains a lack of research investigating microorganisms involved in SSI across various perioperative antibiotic protocols. The purpose of this study was to examine how 2 different prophylactic antibiotic regimens impacted the bacterial profiles of SSI and rate of implant loss after TEBR. METHODS: A single-institution retrospective review of immediate TEBRs between 2001 and 2018 was performed. Surgical site infections requiring hospitalization before stage 2 were included. Highly virulent organisms were defined as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species). Implant loss was defined as removal of tissue expander without immediate replacement. RESULTS: Of 660 TEBRs, 85 (12.9%) developed an SSI requiring hospitalization before stage 2. Fifty-six (65.9%) received less than 24 hours of perioperative intravenous antibiotics and oral antibiotics after discharge (group 1), and 29 (34.1%) received less than 24 hours of intravenous antibiotics only (group 2). There was no significant difference in demographics, preoperative chemotherapy/radiation, acellular dermal matrix usage, or treatment of SSI between groups. In group 1, 64% (n = 36) developed culture positive SSIs, compared with 83% (n = 24) in group 2 (P = 0.076). Staphylococcus aureus was the most common bacteria in both groups. Group 2 demonstrated a significantly increased incidence of gram-positive organisms (46.4% vs 72.4%, P = 0.022) and S. aureus (21.4% vs 55.2%, P = 0.002). However, there was no significant difference in overall highly virulent (P = 0.168), gram-negative (P = 0.416), or total isolated organisms (P = 0.192). Implant loss between groups 1 and 2 (62.5% vs 62.1%, P = 0.969) respectively, was nearly identical. CONCLUSIONS: Our study demonstrates that, despite differences in bacterial profiles between 2 antibiotic protocols, prolonged postoperative antibiotic use did not protect against overall highly virulent infections or implant loss. Antibiotic stewardship guidelines against the overuse of prolonged prophylactic regimens should be considered. Further analysis regarding timing of SSIs and antibiotic treatment is warranted.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Monroig K, Ghosh K, Marquez JE, et al. Do Postoperative Prophylactic Antibiotics Reduce Highly Virulent Infections?: An Analysis of 660 Tissue Expander Breast Reconstructions. Ann Plast Surg. 2020. PMID: 32205491. doi:10.1097/SAP.0000000000002325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。